JP2014510022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510022A5 JP2014510022A5 JP2013546475A JP2013546475A JP2014510022A5 JP 2014510022 A5 JP2014510022 A5 JP 2014510022A5 JP 2013546475 A JP2013546475 A JP 2013546475A JP 2013546475 A JP2013546475 A JP 2013546475A JP 2014510022 A5 JP2014510022 A5 JP 2014510022A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkyl
- hydroxy
- composition according
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 208000003464 asthenopia Diseases 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 4
- 206010015958 Eye pain Diseases 0.000 claims 2
- 206010020675 Hypermetropia Diseases 0.000 claims 2
- 201000009310 astigmatism Diseases 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- 201000006318 hyperopia Diseases 0.000 claims 2
- 230000004305 hyperopia Effects 0.000 claims 2
- 201000010041 presbyopia Diseases 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 206010047513 Vision blurred Diseases 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical group CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims 1
- 229950008081 unoprostone isopropyl Drugs 0.000 claims 1
- 0 CCCC1C*CC1 Chemical compound CCCC1C*CC1 0.000 description 3
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472875P | 2011-04-07 | 2011-04-07 | |
| US61/472,875 | 2011-04-07 | ||
| PCT/JP2012/060094 WO2012137987A1 (en) | 2011-04-07 | 2012-04-06 | Method for treating asthenopia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510022A JP2014510022A (ja) | 2014-04-24 |
| JP2014510022A5 true JP2014510022A5 (enExample) | 2015-05-21 |
Family
ID=46966570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546475A Withdrawn JP2014510022A (ja) | 2011-04-07 | 2012-04-06 | 眼精疲労の処置方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8889735B2 (enExample) |
| EP (1) | EP2694077A4 (enExample) |
| JP (1) | JP2014510022A (enExample) |
| KR (1) | KR20140035363A (enExample) |
| CN (1) | CN103561748A (enExample) |
| CA (1) | CA2830626A1 (enExample) |
| TW (1) | TW201247206A (enExample) |
| WO (1) | WO2012137987A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| MA42953A (fr) | 2015-09-22 | 2018-08-01 | Graybug Vision Inc | Composés et compositions pour le traitement de troubles oculaires |
| WO2018175922A1 (en) | 2017-03-23 | 2018-09-27 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
| MX2019013363A (es) | 2017-05-10 | 2020-01-13 | Graybug Vision Inc | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5225439A (en) | 1987-01-28 | 1993-07-06 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
| US5428062A (en) | 1987-01-28 | 1995-06-27 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| CA1324129C (en) | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
| US5591887A (en) | 1987-04-30 | 1997-01-07 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| US5236907A (en) | 1988-10-01 | 1993-08-17 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
| US5166178B1 (en) | 1987-09-18 | 1998-07-21 | R Tech Ueno Ltd | Ocular hypotensive agents |
| ES2052735T3 (es) | 1987-09-18 | 1994-07-16 | R Tech Ueno Ltd | Un metodo para producir un agente hipotensor ocular. |
| US5151444B1 (en) | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US5194429A (en) | 1988-10-01 | 1993-03-16 | K.K. Ueno Seiyaku Oyo Kenkyujo | Ocular hypotensive agents |
| TW249226B (enExample) | 1990-04-04 | 1995-06-11 | Aderk Ueno Kk | |
| US5221690A (en) | 1991-10-02 | 1993-06-22 | R-Tech Ueno Ltd. | Increasing the choroidal blood flow |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| TW420611B (en) * | 1995-03-10 | 2001-02-01 | R Tech Ueno Ltd | Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder |
| JP3625946B2 (ja) | 1995-03-10 | 2005-03-02 | 株式会社アールテック・ウエノ | 視神経障害改善剤 |
| JP3187438B2 (ja) | 1996-06-10 | 2001-07-11 | 株式会社アールテック・ウエノ | エンドセリン拮抗剤 |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| SE0002211D0 (sv) * | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| MXPA04001604A (es) * | 2001-08-23 | 2004-07-08 | Sucampo Ag | Metodo y composicion para tratamiento de hipertension ocular y glaucoma. |
| WO2008023784A1 (fr) * | 2006-08-25 | 2008-02-28 | Showa University | Agent pour l'amélioration d'un trouble de la circulation ophtalmique |
| KR101405823B1 (ko) * | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
-
2012
- 2012-04-06 WO PCT/JP2012/060094 patent/WO2012137987A1/en not_active Ceased
- 2012-04-06 US US13/441,474 patent/US8889735B2/en not_active Expired - Fee Related
- 2012-04-06 TW TW101112200A patent/TW201247206A/zh unknown
- 2012-04-06 KR KR1020137029521A patent/KR20140035363A/ko not_active Withdrawn
- 2012-04-06 EP EP12768635.0A patent/EP2694077A4/en not_active Withdrawn
- 2012-04-06 CN CN201280027412.3A patent/CN103561748A/zh active Pending
- 2012-04-06 CA CA2830626A patent/CA2830626A1/en not_active Abandoned
- 2012-04-06 JP JP2013546475A patent/JP2014510022A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012107706A8 (en) | Phenothiazine diaminium salts and their use | |
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| RU2009136592A (ru) | Терапевтические агенты | |
| RU2018114518A (ru) | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) | |
| MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
| AR047972A1 (es) | Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas. | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| JP2015508092A5 (enExample) | ||
| JP2019513745A5 (enExample) | ||
| JP2014510022A5 (enExample) | ||
| JP2011510965A (ja) | 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体 | |
| WO2013121449A8 (en) | Compositions and methods for the modulation of specific amidases for n-acylethanolamines for use in the therapy of inflammatory diseases | |
| PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
| MA34094B1 (fr) | Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 | |
| WO2012131656A3 (en) | Compounds for use as therapeutic agents affecting p53 expression and/or activity | |
| RU2012146325A (ru) | Терапевтическое средство или профилактическое средство для лечения фибромиалгии | |
| RU2009128968A (ru) | Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии | |
| JP2010514733A5 (enExample) | ||
| JP2014511825A5 (enExample) | ||
| JP2008528440A5 (enExample) | ||
| KR20250114139A (ko) | 치환된 테트라하이드로피롤로-피리디논 화합물 및 의학적 병태 치료에서의 이의 용도 | |
| JP2012509313A5 (enExample) | ||
| RU2013151166A (ru) | Способ модуляции активности цитокинов | |
| EP2772481A8 (en) | Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof |